

Marion G Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3106158/publications.pdf>

Version: 2024-02-01

54
papers

3,635
citations

257101

24
h-index

197535

49
g-index

56
all docs

56
docs citations

56
times ranked

4411
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1766-1775.	2.4	24
2	A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 2090-2098.	1.9	5
3	Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. <i>American Journal of Transplantation</i> , 2021, 21, 1780-1788.	2.6	14
4	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021, 4, e2037512.	2.8	26
5	Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab511.	0.4	1
6	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. <i>Genes and Immunity</i> , 2020, 21, 348-359.	2.2	5
7	HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. <i>Journal of Public Health</i> , 2019, 41, e283-e289.	1.0	10
8	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Gastroenterology</i> , 2019, 156, 1496-1507.e7.	0.6	32
9	Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1340-1347.	0.6	4
10	Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. <i>Blood</i> , 2019, 133, 137-146.	0.6	88
11	Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy. <i>Aids</i> , 2018, 32, 653-661.	1.0	3
12	Hepatitis C Guidance 2018 Update: AASLD-IDSAS Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 67, 1477-1492.	2.9	509
13	Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now. <i>Clinical Infectious Diseases</i> , 2018, 67, 1493-1497.	2.9	45
14	Hepatitis B virus infection. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18035.	18.1	490
15	Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. <i>Modern Pathology</i> , 2017, 30, 773-783.	2.9	79
16	Histology Rings True. <i>New England Journal of Medicine</i> , 2017, 376, 869-874.	13.9	3
17	Sonography Predicts Liver Steatosis in Patients With Chronic Hepatitis B. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 925-932.	0.8	9
18	Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics. <i>Clinical Infectious Diseases</i> , 2017, 64, 1283-1288.	2.9	19

#	ARTICLE	IF	CITATIONS
19	Human immunodeficiency virus–infected and uninfected adults with non–genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. <i>Hepatology</i> , 2017, 65, 853-863.	3.6	25
20	Screening for hepatocellular carcinoma: What is missing?. <i>Hepatology Communications</i> , 2017, 1, 18-22.	2.0	11
21	Acute and Chronic Hepatitis E Virus Infection in Human Immunodeficiency Virus–Infected U.S. Women. <i>Hepatology</i> , 2016, 63, 712-720.	3.6	40
22	Marijuana Use Is Not Associated With Progression to Advanced Liver Fibrosis in HIV/Hepatitis C Virus–coinfected Women. <i>Clinical Infectious Diseases</i> , 2016, 63, 512-518.	2.9	22
23	Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score. <i>Journal of Infectious Diseases</i> , 2016, 213, 1079-1086.	1.9	18
24	Direct and Indirect Serum Markers of Liver Fibrosis Compared with Transient Elastography among Women in the Women’s Interagency HIV Study. <i>Journal of AIDS & Clinical Research</i> , 2015, 06, .	0.5	4
25	Management of HBV in Pregnancy. <i>Current Hepatology Reports</i> , 2015, 14, 145-152.	0.4	3
26	A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2071-2087.e16.	2.4	90
27	Advances in Therapy for HIV/Hepatitis C Virus-Coinfected Patients in the Liver Transplant Setting. <i>Clinical Infectious Diseases</i> , 2015, 60, 108-116.	2.9	46
28	Survey of Asian Patients with Hepatitis B Infection: Limited Knowledge of Transmission and Screening of Family Members. <i>Journal of Immigrant and Minority Health</i> , 2015, 17, 112-117.	0.8	6
29	Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e68152.	1.1	75
30	Special populations with hepatitis B virus infection. <i>Hepatology</i> , 2009, 49, S146-S155.	3.6	40
31	The challenge of diagnosing autoimmune hepatitis: Less is more. <i>Hepatology</i> , 2008, 48, 10-12.	3.6	15
32	Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. <i>Aids</i> , 2008, 22, 1399-1410.	1.0	149
33	Hepatitis Virus Infections. , 2008, , 415-423.		2
34	Prevalence and Long-Term Effects of Occult Hepatitis B Virus Infection in HIV-Infected Women. <i>Clinical Infectious Diseases</i> , 2007, 45, 736-740.	2.9	39
35	Tenofovir disoproxil fumarate for the treatment of hepatitis B virus infection: pharmacokinetics and clinical efficacy. <i>Therapy: Open Access in Clinical Medicine</i> , 2007, 4, 141-151.	0.2	0
36	Viral Hepatitis in HIV Infection. <i>New England Journal of Medicine</i> , 2007, 356, 1445-1454.	13.9	282

#	ARTICLE	IF	CITATIONS
37	HIV and liver disease forum: Conference proceedings. Hepatology, 2007, 45, 1566-1577.	3.6	32
38	Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology, 2007, 46, 769-775.	3.6	56
39	Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatology International, 2007, 1, 316-325.	1.9	20
40	Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology, 2006, 44, 1110-1116.	3.6	178
41	Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology, 2005, 42, 1184-1193.	3.6	112
42	Recurrent primary biliary cirrhosis: Peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transplantation, 2005, 11, 1252-1257.	1.3	85
43	Managing hepatitis B coinfection in HIV-infected patients. Current HIV/AIDS Reports, 2005, 2, 122-126.	1.1	8
44	Prolonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2004, 99, 264-268.	0.2	46
45	Antiviral therapy: nucleotide and nucleoside analogs. Clinics in Liver Disease, 2004, 8, 371-385.	1.0	23
46	Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical) Tj ETQq0 0 0 rgBT /Overlock 10		